Trump's Drug Pricing Plan Expands to Include Nine New Pharmaceutical Companies
This expansion brings the total number of participating manufacturers to 26, covering approximately 89% of the branded drug market. The agreements address critical treatments for conditions such as hemophilia, Parkinson's disease, and various cancers, aiming to make essential medications more affordable.


